AstraZeneca Reports Mixed Phase 3 Results for Rare Bone Disease Drug

Key Facts

1Phase 3 HICKORY trial data for efzimfotase alfa showed improvements in secondary endpoints for hypophosphatasia (HPP).

2The drug missed its primary trial goal despite showing other clinical improvements.

AstraZeneca reported mixed results from its Phase 3 HICKORY trial for efzimfotase alfa, a treatment for hypophosphatasia (HPP). The drug missed its primary clinical trial goal despite showing other notable improvements, Benzinga reported. Data from the study indicated that the treatment met secondary endpoints, highlighting clinical progress for patients with the rare bone disorder.

AZN closed at $159.20 on October 9, 2026, with the stock reaching a session high of $160.07 and a low of $158.53. These clinical developments occur as the company continues its focus on rare disease therapies, balancing the missed primary endpoint against the observed improvements in secondary clinical measures.